Enanta Pharmaceuticals Company Insiders

ENTA Stock  USD 8.22  0.27  3.18%   
About 80 percent of Enanta Pharmaceuticals' insiders are selling. The analysis of the overall insider sentiment regarding Enanta Pharmaceuticals suggests that a fairly large number of insiders are terrified. Enanta Pharmaceuticals employs about 131 people. The company is managed by 11 executives with a total tenure of roughly 70 years, averaging almost 6.0 years of service per executive, having 11.91 employees per reported executive.
Jay Luly  CEO
CEO and President and Director

Insider Sentiment 20

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-02-12Jay R LulyAcquired 45000 @ 5.69View
2024-12-06Tara Lynn KiefferDisposed 2283 @ 8.06View
2024-07-15Scott T RottinghausDisposed 5375 @ 17.08View
2024-07-11Scott T RottinghausDisposed 4299 @ 15.07View
2024-06-17Tara Lynn KiefferDisposed 7266 @ 12.33View
Monitoring Enanta Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

Enanta Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Enanta Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Enanta will maintain a workforce of about 130 employees by March 2025.
 
Yuan Drop
 
Covid

Enanta Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.1775) % which means that it has lost $0.1775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.691) %, meaning that it created substantial loss on money invested by shareholders. Enanta Pharmaceuticals' management efficiency ratios could be used to measure how well Enanta Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.34. The current year's Return On Capital Employed is expected to grow to -0.42. At present, Enanta Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 5.6 M, whereas Total Assets are forecasted to decline to about 333.8 M.
As of February 26, 2025, Common Stock Shares Outstanding is expected to decline to about 18.4 M. The current year's Net Loss is expected to grow to about (104.1 M)

Enanta Pharmaceuticals Workforce Comparison

Enanta Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,470. Enanta Pharmaceuticals holds roughly 131 in number of employees claiming about 5% of equities under Health Care industry.

Enanta Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of (1.58) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.39) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.39.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.780.87
Moderately Down
Slightly volatile

Enanta Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enanta Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enanta Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Enanta Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
1.1667
7
6
 112,500 
 24,647 
2024-12-01
0.6364
7
11
 736,000 
 24,281 
2024-09-01
0.2
1
5
 5,375 
 18,786 
2024-06-01
1.0
1
1
 150,000 
 7,266 
2024-03-01
1.75
14
8
 124,323 
 12,498 
2023-12-01
0.5
7
14
 768,000 
 46,623 
2023-06-01
1.0
1
1
 6,667 
 6,667 
2023-03-01
1.1905
25
21
 315,853 
 193,880 
2022-12-01
1.3846
18
13
 582,648 
 88,468 
2022-06-01
0.4615
6
13
 83,344 
 170,168 
2022-03-01
1.7059
29
17
 156,111 
 118,669 
2021-12-01
0.8636
19
22
 385,270 
 85,597 
2021-09-01
1.0
1
1
 13,144 
 4,516 
2021-03-01
3.0
9
3
 126,193 
 16,021 
2020-12-01
1.5
18
12
 383,922 
 38,613 
2020-09-01
1.0
1
1
 1,666 
 1,666 
2020-06-01
2.0
2
1
 18,740 
 1,740 
2020-03-01
2.0
16
8
 74,681 
 19,787 
2019-12-01
1.0
12
12
 264,519 
 46,007 
2019-09-01
1.0
1
1
 5,000 
 5,000 
2019-06-01
2.0
2
1
 6,590 
 3,295 
2019-03-01
0.9412
32
34
 224,116 
 195,955 
2018-12-01
1.2222
11
9
 193,500 
 55,500 
2018-09-01
0.1538
4
26
 17,363 
 69,873 
2018-06-01
0.2105
4
19
 15,825 
 68,360 
2018-03-01
1.7273
19
11
 113,774 
 36,161 
2017-06-01
4.0
4
1
 57,125 
 29,274 
2017-03-01
1.5714
11
7
 51,320 
 20,711 
2016-12-01
13.0
13
1
 347,500 
 13,921 
2016-06-01
1.5
3
2
 67,145 
 66,645 
2016-03-01
2.5714
18
7
 199,339 
 133,705 
2015-12-01
1.375
11
8
 334,200 
 82,200 
2015-06-01
0.2
1
5
 90,000 
 54,000 
2015-03-01
1.3333
12
9
 90,404 
 100,544 
2014-12-01
0.5833
7
12
 243,805 
 47,055 
2014-09-01
0.2
2
10
 12,149 
 61,149 
2014-06-01
0.1
1
10
 82,500 
 35,000 
2014-03-01
0.3077
16
52
 649,451 
 1,562,131 
2013-12-01
0.2059
7
34
 199,280 
 338,369 
2013-09-01
0.2
1
5
 84,265 
 98,565 
2013-03-01
0.4714
33
70
 9,366,983 
 36,002,188 

Enanta Pharmaceuticals Notable Stakeholders

An Enanta Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Enanta Pharmaceuticals often face trade-offs trying to please all of them. Enanta Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Enanta Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jay LulyCEO and President and DirectorProfile
Paul MellettCFO and Sr. VP of Fin. and Admin.Profile
Yat OrChief Scientific Officer and Sr. VP of RandDProfile
Nathaniel JDGeneral VPProfile
Scott MDSenior OfficerProfile
Nathalie MDConsultantProfile
Jennifer VieraExecutive CommunicationsProfile
Tara KiefferSenior DevelopmentProfile
Brendan LuuSenior DevelopmentProfile
Matthew JDChief SecretaryProfile
Scott RottinghausVP OfficerProfile

About Enanta Pharmaceuticals Management Performance

The success or failure of an entity such as Enanta Pharmaceuticals often depends on how effective the management is. Enanta Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Enanta management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Enanta management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.35)(0.34)
Return On Capital Employed(0.44)(0.42)
Return On Assets(0.35)(0.34)
Return On Equity(1.04)(0.98)
Please note, the presentation of Enanta Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enanta Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Enanta Pharmaceuticals' management manipulating its earnings.

Enanta Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Enanta Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Enanta Pharmaceuticals within its industry.

Enanta Pharmaceuticals Manpower Efficiency

Return on Enanta Pharmaceuticals Manpower

Revenue Per Employee516.3K
Revenue Per Executive6.1M
Net Loss Per Employee885.8K
Net Loss Per Executive10.5M
Working Capital Per Employee1.8M
Working Capital Per Executive22M

Complementary Tools for Enanta Stock analysis

When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Stocks Directory
Find actively traded stocks across global markets
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine